Ligand id: 9172

Name: olaratumab

No information available.
Summary of Clinical Use
Soft tissue sarcoma (STS): Olaratumab plus doxorubicin was approved by the US FDA in October 2016, for patients.with advanced STS. Additional clinical trials include Phase 1/2 NCT02659020 evaluating gemcitabine and docetaxel with or without olaratumab in patients with STS.
Other cancers: Phase 2 trials NCT01204710 (prostate cancer, plus mitoxantrone) and NCT00913835 (ovarian cancer, plus liposomal doxorubicin) have been completed. Paclitaxel plus carboplatin ± olaratumab in non-small cell lung cancer is in Phase 2 assessment. Recurrent glioblastoma multiforme and gastrointestinal stromal tumors (GIST) have also reached Phase 2 trials.
Mechanism Of Action and Pharmacodynamic Effects
Coexpression of PDGFRα and PDGFs, consistent with autocrine-mediated growth, has been reported in sarcomas and glioblastomas. Hence PDGFRα antibodies are being developed to abbrogate aberrant PDGFRα signalling and uncontrolled proliferation in cancers expressing PDGFRα.
Eli Lilly have produced a mechanism of action video for olaratumab, which you can access here.